drugset / Trial / NCT01449942

Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

NCT01449942 ↗

Phase 1/2 Completed 40 enrolled Xiangya Hospital of Central South University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.

Timeline

Start
2009-05
Primary completion
2011-04
Completion
2011-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DZ1 Unknown 12 mg Other